Nichi-Iko Of Japan Invests ¥7.3 Billion To Build New Production Facility
This article was originally published in PharmAsia News
Executive Summary
Toyama-based generic drug maker Nichi-Iko Pharmaceutical announced it will build a new production facility in Katsukawa, Toyama prefecture. Chiyoda TechnoAce, a subsidiary of Yokohama-based Chiyoda Corp has been awarded the ¥7.3 billion construction contract. Construction starts this September and will be completed by October 2009. Actual production is expected to start in December 2009. The Japanese generics market has been growing and generics makers are speeding up facility investment and the integration of production and research facilities to boost efficiency. (Click here for more - Japanese language
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.